Phase 2 Clinical Trial

Key facts

Defined in

21 CFR 312.21(b)

Typical size (FDA regulation)

Usually no more than several hundred subjects

Participants

Patients with the disease or condition under study

Common subtypes (industry usage)

Phase 2a proof of concept, Phase 2b dose ranging

Regulatory milestone

End-of-Phase 2 meeting with FDA, described in 21 CFR 312.47

What is a Phase 2 clinical trial?

Phase 2 is where an investigational drug first has to show that it may work. FDA regulations describe Phase 2 as controlled clinical studies that evaluate effectiveness for a particular indication in patients with the disease and determine the common short-term side effects and risks, typically in a relatively small number of patients.

The phase answers two practical questions for the sponsor. Is there enough signal of benefit to justify a larger and far more expensive Phase 3 program? And which dose and regimen should that program use?

How Phase 2 trials are designed

Phase 2 designs vary by therapeutic area, and the 2a and 2b labels are industry conventions rather than regulatory categories. Common patterns include:

• Phase 2a: smaller proof-of-concept studies that look for a biological or clinical signal.
• Phase 2b: larger, often randomized, dose-ranging studies that compare several doses with placebo or another control.
• Single-arm studies: every participant receives the drug and results are compared with historical data, common in oncology and rare diseases.
• Seamless Phase 2/3 designs: one protocol that moves from dose selection into confirmatory testing without starting a new trial.

Why Phase 2 trials matter

Many drug candidates stop in Phase 2 because they do not show enough effectiveness or reveal safety problems, which makes Phase 2 readouts closely watched events for investors, licensing teams and competitors.

Before Phase 3, sponsors commonly hold an End-of-Phase 2 meeting with FDA to agree on the design of the pivotal program, including endpoints and the study population. Analysts use the Phase 2 design and results to forecast the likely label, the treatable population and the timing of an approval filing.

For site selection teams, sites that enrolled well in a Phase 2 study are strong candidates for the larger Phase 3 program that follows.